Carregant...

Discovery of direct inhibitor of KRAS oncogenic protein by natural products: a combination of pharmacophore search, molecular docking, and molecular dynamic studies

BACKGROUND AND PURPOSE: Aberrant signaling by oncogenic RAS proteins occurs in almost all human tumors. One of the promising strategies to overcome such cancers is the inhibition of KRAS protein, a subtype of RAS family involved in cell growth, differentiation, and apoptosis, through preventing its...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Res Pharm Sci
Autors principals: Hashemi, Samaneh, Sharifi, Amirhossein, Zareei, Sara, Mohamedi, Ghazale, Biglar, Mahmood, Amanlou, Massoud
Format: Artigo
Idioma:Inglês
Publicat: Wolters Kluwer - Medknow 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540812/
https://ncbi.nlm.nih.gov/pubmed/33088323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1735-5362.288425
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!